MA47179A - Composition d'acide dicarboxylique mannuronique - Google Patents
Composition d'acide dicarboxylique mannuroniqueInfo
- Publication number
- MA47179A MA47179A MA047179A MA47179A MA47179A MA 47179 A MA47179 A MA 47179A MA 047179 A MA047179 A MA 047179A MA 47179 A MA47179 A MA 47179A MA 47179 A MA47179 A MA 47179A
- Authority
- MA
- Morocco
- Prior art keywords
- mannuronic
- composition
- dicarboxylic acid
- dicarboxylic
- acid
- Prior art date
Links
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016113879 | 2016-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47179A true MA47179A (fr) | 2019-11-06 |
Family
ID=62706915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047179A MA47179A (fr) | 2016-12-30 | 2017-12-27 | Composition d'acide dicarboxylique mannuronique |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11384111B2 (fr) |
| EP (1) | EP3563853B1 (fr) |
| JP (1) | JP6977059B2 (fr) |
| KR (1) | KR102539060B1 (fr) |
| CN (1) | CN108283647B (fr) |
| AU (1) | AU2017385332B2 (fr) |
| CA (1) | CA3048554C (fr) |
| EA (1) | EA201991615A1 (fr) |
| MA (1) | MA47179A (fr) |
| MY (1) | MY192462A (fr) |
| PH (1) | PH12019550107A1 (fr) |
| UA (1) | UA127034C2 (fr) |
| WO (1) | WO2018121559A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017385332B2 (en) | 2016-12-30 | 2020-10-29 | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Composition of mannuronic dicarboxylic acid |
| US12098162B2 (en) * | 2017-11-13 | 2024-09-24 | Extremochem, Lda | Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules |
| CN110652517A (zh) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | 褐藻胶寡糖二酸的组合物 |
| CN110652525A (zh) | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | 甘露糖醛二酸的组合物在治疗炎症中的应用 |
| CN110652523A (zh) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | 甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用 |
| CN110652526A (zh) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | 甘露糖醛二酸的组合物在治疗糖尿病中的应用 |
| CN110652516A (zh) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用 |
| CN112336742A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 甘露糖醛酸寡糖治疗Th1主导相关疾病的用途 |
| CN112336860A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 通过调节肠道微生物治疗阿尔茨海默病的方法 |
| CN112336876A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 用于识别阿尔茨海默病患者中的糖类药物敏感性患者的方法 |
| CN112336861A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 通过调节氨基酸水平治疗阿尔茨海默病的方法 |
| CN112741838A (zh) * | 2019-10-31 | 2021-05-04 | 上海绿谷制药有限公司 | 含有褐藻胶寡糖二酸的药用组合物 |
| CN110755440B (zh) * | 2019-11-20 | 2023-02-28 | 中国海洋大学 | 川芎嗪和甘露糖醛酸的组合物在用于制备治疗血栓性疾病和神经系统疾病的药物中的应用 |
| CN113527374B (zh) * | 2020-04-22 | 2025-12-02 | 中国科学院上海有机化学研究所 | 一种甘露糖醛酸寡糖的制备方法及其中间体 |
| CN113244445A (zh) * | 2021-05-24 | 2021-08-13 | 广州市尚信净化工程有限公司 | 一种氧化亚铜-氧化刺槐豆胶抗菌凝胶 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562050A (zh) | 2004-03-24 | 2005-01-12 | 中国海洋大学 | 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用 |
| CN100508985C (zh) | 2004-03-24 | 2009-07-08 | 中国海洋大学 | 褐藻胶寡糖及其衍生物及其制备方法和用途 |
| JP2016108474A (ja) * | 2014-12-08 | 2016-06-20 | 栄治 松村 | オリゴ糖の製造方法およびオリゴ糖 |
| CN106344594A (zh) | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在治疗炎症中的应用 |
| CN106344593B (zh) * | 2015-07-17 | 2020-01-10 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在制备治疗血管性痴呆药物中的应用 |
| CN106349298B (zh) * | 2015-07-17 | 2021-02-09 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在改善睡眠障碍中的应用 |
| CN106344595B (zh) | 2015-07-17 | 2020-06-19 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在制备治疗疼痛药物中的应用 |
| CN106344592A (zh) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用 |
| AU2017385332B2 (en) | 2016-12-30 | 2020-10-29 | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Composition of mannuronic dicarboxylic acid |
-
2017
- 2017-12-27 AU AU2017385332A patent/AU2017385332B2/en active Active
- 2017-12-27 WO PCT/CN2017/118843 patent/WO2018121559A1/fr not_active Ceased
- 2017-12-27 UA UAA201908582A patent/UA127034C2/uk unknown
- 2017-12-27 MA MA047179A patent/MA47179A/fr unknown
- 2017-12-27 KR KR1020197022102A patent/KR102539060B1/ko active Active
- 2017-12-27 MY MYPI2019003786A patent/MY192462A/en unknown
- 2017-12-27 CA CA3048554A patent/CA3048554C/fr active Active
- 2017-12-27 EA EA201991615A patent/EA201991615A1/ru unknown
- 2017-12-27 JP JP2019556407A patent/JP6977059B2/ja active Active
- 2017-12-27 US US16/474,928 patent/US11384111B2/en active Active
- 2017-12-27 EP EP17888733.7A patent/EP3563853B1/fr active Active
- 2017-12-28 CN CN201711467596.6A patent/CN108283647B/zh active Active
-
2019
- 2019-06-27 PH PH12019550107A patent/PH12019550107A1/en unknown
-
2022
- 2022-07-08 US US17/860,468 patent/US12269838B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12269838B2 (en) | 2025-04-08 |
| BR112019013459A2 (pt) | 2019-12-31 |
| EP3563853A1 (fr) | 2019-11-06 |
| JP6977059B2 (ja) | 2021-12-08 |
| CN108283647B (zh) | 2021-01-15 |
| US20220356202A1 (en) | 2022-11-10 |
| KR20190101420A (ko) | 2019-08-30 |
| MY192462A (en) | 2022-08-22 |
| CA3048554A1 (fr) | 2018-07-05 |
| CN108283647A (zh) | 2018-07-17 |
| AU2017385332B2 (en) | 2020-10-29 |
| EP3563853A8 (fr) | 2020-06-17 |
| WO2018121559A1 (fr) | 2018-07-05 |
| NZ754947A (en) | 2021-03-26 |
| KR102539060B1 (ko) | 2023-06-02 |
| JP2020507619A (ja) | 2020-03-12 |
| AU2017385332A1 (en) | 2019-07-18 |
| EA201991615A1 (ru) | 2019-12-30 |
| EP3563853A4 (fr) | 2021-01-06 |
| PH12019550107A1 (en) | 2020-06-01 |
| UA127034C2 (uk) | 2023-03-22 |
| EP3563853C0 (fr) | 2025-08-06 |
| EP3563853B1 (fr) | 2025-08-06 |
| WO2018121559A8 (fr) | 2023-03-30 |
| CA3048554C (fr) | 2022-11-29 |
| US20200385417A1 (en) | 2020-12-10 |
| US11384111B2 (en) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47179A (fr) | Composition d'acide dicarboxylique mannuronique | |
| EP3681854A4 (fr) | Formation d'esters d'acide téréphtalique | |
| MA41999A (fr) | Compositions d'acide obéticholique et procédés d'utilisation | |
| EP3517528A4 (fr) | Sel d'addition d'acide de dérivé de benzimidazole | |
| EP3491149A4 (fr) | Traitement d'acide nucléique indépendant | |
| EP3368089C0 (fr) | Formulations de nanoparticules pour l'administration de complexes d'acide nucléique | |
| EP2971161A4 (fr) | Purification d'acide ribonucléique | |
| MA42615A (fr) | Composés phosphodiamide antiviraux d'ester d'acide bêta-aminé | |
| EP2970961A4 (fr) | Amplification d'acide nucléique | |
| EP3277808A4 (fr) | Production acellulaire d'acide ribonucléique | |
| FR3015290B1 (fr) | Compositions d'acide hyaluronique compreant de la mepivacaine | |
| DK3290501T3 (da) | Detergent compositions containing alkoxylated fatty acid amides | |
| EP3587576A4 (fr) | Acide oligonucléique anti-sens | |
| EP3390457A4 (fr) | Fabrication de nanocellulose et d'intermédiaires de celle-ci en utilisant de d'acide oxalique dihydraté | |
| EP3501517A4 (fr) | Agent d'injection d'acide tout-trans | |
| EP3113613A4 (fr) | Compositions d'ester de choline de l'acide lipoïque et procédés d'utilisation correspondants | |
| EP3394099A4 (fr) | Formulations d'anticorps anti-il-10 modifiés | |
| FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
| EP3414256A4 (fr) | Sel d'amine de l'acide obéticholique | |
| EP3518995C0 (fr) | Composition d'alpha-tcp, de silicate et d'acide aminé phosphorylé | |
| EP3600279A4 (fr) | Formulations d'acide 1-amino-1-cyclopropanecaboxylique | |
| EP3594345A4 (fr) | Acide nucléique capable d'inhiber l'expression de masp2 | |
| EP3283115C0 (fr) | Compositions pour le traitement de l'autisme | |
| EP3316677A4 (fr) | Activateur de passage d'acide jasmonique | |
| EP3447059A4 (fr) | Sel d'ester d'acide sulfurique contenant du silicium |